WO2018213872A1 - "systems and methods for monitoring neural activity" - Google Patents

"systems and methods for monitoring neural activity" Download PDF

Info

Publication number
WO2018213872A1
WO2018213872A1 PCT/AU2018/050486 AU2018050486W WO2018213872A1 WO 2018213872 A1 WO2018213872 A1 WO 2018213872A1 AU 2018050486 W AU2018050486 W AU 2018050486W WO 2018213872 A1 WO2018213872 A1 WO 2018213872A1
Authority
WO
WIPO (PCT)
Prior art keywords
stimulus
hfos
electrode
bursts
waveform characteristics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/AU2018/050486
Other languages
English (en)
French (fr)
Inventor
Nicholas SINCLAIR
Hugh Mcdermott
James Fallon
Thushara PERERA
Wes THEVATHASAN
Kristian BULLUSS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bionics Institute
Original Assignee
Bionics Institute of Australia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017901934A external-priority patent/AU2017901934A0/en
Priority claimed from PCT/AU2017/050809 external-priority patent/WO2018027259A1/en
Application filed by Bionics Institute of Australia filed Critical Bionics Institute of Australia
Priority to US16/616,017 priority Critical patent/US11298070B2/en
Priority to CN201880047032.3A priority patent/CN111200967B/zh
Priority to JP2019564887A priority patent/JP7144450B2/ja
Priority to EP18804979.5A priority patent/EP3629913B1/en
Publication of WO2018213872A1 publication Critical patent/WO2018213872A1/en
Anticipated expiration legal-status Critical
Priority to US17/691,491 priority patent/US20220192579A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/316—Modalities, i.e. specific diagnostic methods
    • A61B5/369—Electroencephalography [EEG]
    • A61B5/377—Electroencephalography [EEG] using evoked responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/0526—Head electrodes
    • A61N1/0529—Electrodes for brain stimulation
    • A61N1/0534—Electrodes for deep brain stimulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
    • A61N1/36067—Movement disorders, e.g. tremor or Parkinson disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
    • A61N1/36082—Cognitive or psychiatric applications, e.g. dementia or Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/36128—Control systems
    • A61N1/36135—Control systems using physiological parameters
    • A61N1/36139—Control systems using physiological parameters with automatic adjustment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/36128—Control systems
    • A61N1/36146—Control systems specified by the stimulation parameters

Definitions

  • the present disclosure relates to deep brain stimulation (DBS) and, in particular, methods and systems of monitoring neural activity during DBS.
  • DBS deep brain stimulation
  • DBS Deep brain stimulation
  • STN subthalamic nucleus
  • GPi globus pallidus interna
  • Stimulation parameters can be adjusted using a controller external to the body, remotely connected to the neurostimulator.
  • DBS devices Whilst established DBS technology has proven to be effective in alleviating movement disorder symptoms, there are several limitations to state of the art devices. In particular, established techniques for intraoperative testing of DBS electrodes to ensure correct positioning in the brain, such as x-ray imaging, microelectrode recordings, and clinical assessment can be inaccurate. Consequently, electrodes are often implanted in suboptimal locations, resulting in diminished therapeutic outcomes and unwanted side-effects. After implantation, DBS devices require manual adjustment by a clinician. This typically involves the clinician adjusting parameters of the stimulus based on a largely subjective assessment of immediate or short-term improvement of the patient's symptoms.
  • a method for monitoring neural activity responsive to a stimulus in a brain comprising:
  • HFOs high frequency oscillations
  • generating a second stimulus comprising a second plurality of bursts of stimulation, wherein one or more waveform characteristics of the second stimulus is dependent on the one of more waveform characteristics of the HFOs;
  • the first plurality of bursts may comprise a first burst applied for a first time period and having a first waveform characteristic and at least a second burst applied for a second time period following the first time period and having a second waveform characteristic.
  • Detecting HFOs due to neuronal activity at one or more of the at least one electrode implanted in the brain may further comprise: detecting a first high frequency oscillation (HFO) during the first time period and at least a second HFO during the second time period at one or more of the at least one electrode implanted in the brain.
  • HFO high frequency oscillation
  • the one or more waveform characteristics of the HFOs may comprise one or more waveform characteristics of the first and at least second HFOs.
  • the one or more waveform characteristics of the HFOs may comprise one or more of the following:
  • the first and second waveform characteristics may comprise one or more of the following: a) a frequency
  • One or more of the plurality of bursts may comprise one of: a) a symmetric waveform having a first phase and a second phase of opposite polarity to the first phase; and b) a biphasic waveform having a first phase at a first amplitude for a first duration and a second phase of opposite polarity to the first phase, the second phase having a second amplitude and a second duration, the product of the first amplitude and the first duration being substantially equal to the product of the second amplitude and the second duration.
  • the first stimulus and/or the second stimulus may be a therapeutic stimulus or a non- therapeutic stimulus.
  • the first plurality of bursts may be separated by a first pattern time period, each of the first plurality of bursts comprising a plurality of pulses separated by a second pattern time period.
  • the first pattern time period may be greater than the second pattern time period.
  • the second plurality of bursts may be separated by a first pattern time period, each of the first plurality of bursts comprising a plurality of pulses separated by a second pattern time period.
  • the first pattern time period may be greater than the second pattern time period.
  • the first pattern time period may equal to the second pattern time period.
  • Two or more of pulses within at least one of the first plurality of bursts may have different amplitudes.
  • Two or more of pulses within at least one of the second plurality of bursts may have different amplitudes.
  • the different amplitudes may be selected to produce a ramp in amplitude of sequential pulses in the at least one of the bursts of the first plurality of bursts or the second plurality of bursts.
  • the amplitude of a final pulse in each of the first plurality of bursts may be substantially identical. Equally, the amplitude of a final pulse in each of the second plurality of bursts may be substantially identical.
  • the one or more waveform characteristics of the second stimulus may comprise a frequency which is configured in dependence of a characteristic of the detected HFOs.
  • the frequency may be configured to be equal to the frequency of the HFO divided by 1, 2, 3 or 4.
  • the one or more waveform characteristics of the HFOs may comprise a rate of change of frequency.
  • the one or more characteristics of the second stimulus may be configured to maximise the rate of change of the frequency of the HFOs.
  • the frequency of the HFOs being detected is preferably between 200 Hz and 500 Hz.
  • the method may further comprise: determining a correlation between the detected HFOs and a HFO template; and generating the second stimulus based on the correlation.
  • the method may further comprise: determining a correlation betweenthe one or more determined waveform characteristics of the HFOs with one or more predetermined threshold values; and generating the second stimulus based on the correlation.
  • the method may further comprise: estimating a patient state of a patient based on the determined one or more waveform characteristics of the HFOs. [0028] The method may further comprise: diagnosing the patient based on the estimate of the patient's state.
  • the method may further comprise: generating one or more alerts associated with the estimated patient state; and outputting the one or more alerts.
  • the method may further comprise: whilst applying the second stimulus, simultaneously detecting high frequency oscillations (HFOs) due to neuronal activity at one or more of the at least one electrode implanted in the brain; and determining one or more second waveform characteristics of the detected second resonant response.
  • HFOs high frequency oscillations
  • the method may further comprise: estimating a degree of progression of a disease associated with the patient based on the one or more first waveform characteristics of the HFOs and the one or more second waveform characteristics of the HFOs.
  • the method may further comprise: determining the effect of a therapy provided to the patient based on the one or more first waveform characteristics of the HFOs and the one or more second waveform characteristics of the HFOs.
  • the therapy may comprise one or more of medication and deep brain stimulation.
  • the at least one electrode may comprise two or more electrodes located within different neural structures in the brain.
  • the at least one electrode may comprise two or more electrodes located within different hemispheres of the brain.
  • the method may further comprise: whilst applying the second stimulus, simultaneously determining one or more second waveform characteristics of the HFOs.
  • the method may further comprise: comparing a common waveform characteristic between the one or more waveform characteristics and the one or more second waveform characteristics.
  • the method may further comprise: comparing a degree of change of a common waveform characteristic between the one or more waveform characteristics and the one or more second waveform characteristics.
  • the method may further comprise: comparing a rate of change of a common waveform characteristic between the one or more waveform characteristics and the one or more second waveform characteristics.
  • the steps of applying the second stimulus whilst simultaneously determining one or more second waveform characteristics of the HFOs may be repeated until it is determined that one or more of the at least one electrode is positioned in a target neural structure in the brain.
  • the method may further comprise: selecting one or more of the at least one electrode to use for therapeutic stimulation of a target neural structure in the brain based on the one or more waveform characteristics or the one or more second waveform characteristics; and applying a therapeutic stimulus to the target neural structure via the selected one or more of the at least one electrode.
  • the method may further comprise: inserting the at least one electrode into the brain along a predefined trajectory; wherein the steps of applying the second stimulus whilst simultaneously determining one or more second waveform characteristics of the HFOs are repeated while the at least one electrode is being inserted to generate a profile of HFO activity with respect to the predefined trajectory and a target neural structure in the brain
  • the profile of HFO activity may be used to determine a position of the one or more electrodes relative to the target neural structure.
  • the at least one electrode may comprise a plurality of electrodes.
  • the steps of applying the second stimulus whilst simultaneously determining one or more second waveform characteristics of the HFOs may be repeated using different combinations of the at least one electrode to generate a profile of HFO activity for the different combinations of the at least one electrode.
  • the method may further comprise: selecting one or more of the at least one electrode based on the profile of HFO activity; and applying a therapeutic stimulus to the selected one or more of the at least one electrode.
  • the selected one or more of the at least one electrode may comprises a plurality of electrodes.
  • the method may further comprise:
  • a neuromodulation system comprising:
  • a lead having at least one electrode adapted for implantation in or near a target neural structure in the brain;
  • a signal generator selectively coupled to one or more of the at least one electrode and configured to:
  • a measurement device selectively coupled to one or more of the at least one electrode and configured to detect high frequency oscillations (HFOs) generated from neural activity at one or more of the at least one electrode when implanted in the brain at least partially during application of the first stimulus; and
  • HFOs high frequency oscillations
  • a processing unit coupled to the measurement device and configured to determine one or more waveform characteristics of the detected HFOs
  • the first plurality of bursts may comprise a first burst applied for a first time period and having a first waveform characteristic and at least a second burst applied for a second time period following the first time period and having a second waveform characteristic.
  • the measurement device may be configured to: detect a first high frequency oscillation (HFO) during the first time period and at least a second HFO during the second time period at one or more of the at least one electrode implanted in the brain.
  • HFO high frequency oscillation
  • the one or more waveform characteristics of the HFOs may comprise one or more waveform characteristics of the first and at least second HFOs.
  • the one or more waveform characteristics of the HFOs may comprise one or more of the following:
  • the first and second waveform characteristics may comprise one or more of the following: a) a frequency
  • One or more of the plurality of bursts may comprise one of: a) a symmetric waveform having a first phase and a second phase of opposite polarity to the first phase; and b) a biphasic waveform having a first phase at a first amplitude for a first duration and a second phase of opposite polarity to the first phase, the second phase having a second amplitude and a second duration, the product of the first amplitude and the first duration being substantially equal to the product of the second amplitude and the second duration.
  • the first stimulus and/or the second stimulus may be a therapeutic stimulus or a non- therapeutic stimulus.
  • the first plurality of bursts may be separated by a first pattern time period, each burst comprising a plurality of pulses separated by a second pattern time period. Additionally or alternatively, the first plurality of bursts may be separated by a first pattern time period, each burst comprising a plurality of pulses separated by a second pattern time period.
  • the first pattern time period may greater than the second pattern time period.
  • the first pattern time period may be greater than or equal to the second pattern time period.
  • Two or more pulses within at least one of the first plurality of bursts may have different amplitudes. Additionally or alternatively, two or more of pulses within at least one of the second plurality of bursts may have different amplitudes. [0059] The different amplitudes may be selected to produce a ramp in amplitude of sequential pulses in the at least one of the bursts of the first plurality of bursts or the second plurality of bursts.
  • the amplitude of a final pulse in each of the first plurality of bursts may be substantially identical. Additionally or alternatively, the amplitude of a final pulse in each of the second plurality of bursts may be substantially identical.
  • the one or more waveform characteristics of the second stimulus may comprise a frequency which is configured in dependence of the frequency the detected HFOs.
  • the frequency may be configured to be equal to the frequency of the first and/or second HFO divided by 1, 2, 3 or 4.
  • the one or more waveform characteristics of the HFOs may comprise a rate of change of frequency.
  • the one or more characteristics of the one or more waveform characteristics of the second stimulus may be configured to maximise the rate of change of the frequency of the HFOs.
  • the frequency of the HFOs being detected is preferably between 200 Hz and 500 Hz.
  • the system may further correlating the detected HFOs with an HFO template; and generating the second stimulus based on the correlation.
  • the processing unit may be further configured to: determine a correlation between the detected HFOs and an HFO template; and generating the second stimulus based on the correlation.
  • the processing unit may be further configured to: determine a correlation between the one or more determined waveform characteristics of the HFOs and one or more predetermined threshold values; and generate the second stimulus based on the correlation.
  • the processing unit may be further configured to: estimate a patient state of a patient based on the determined one or more waveform characteristics of the HFOs.
  • the processing unit may be further configured to: diagnose the patient based on the estimate of the patient's state.
  • the processing unit may be further configured to: generate one or more alerts associated with the estimated patient state; and outputting the one or more alerts.
  • the processing unit may be further configured to: whilst applying the second stimulus, simultaneously detect high frequency oscillations (HFOs) due to neuronal activity at one or more of the at least one electrode implanted in the brain; and determine one or more second waveform characteristics of the detected HFOs during application of the second stimulus.
  • HFOs high frequency oscillations
  • the processing unit may be further configured to: estimate a degree of progression of a disease associated with the patient based on the one or more first waveform characteristics of the HFOs and the one or more second waveform characteristics of the HFOs.
  • the processing unit may be further configured to: determine the effect of a therapy provided to the patient based on the one or more first waveform characteristics of the HFOs and the one or more second waveform characteristics of the HFOs.
  • the therapy may be medication or deep brain stimulation.
  • the at least one electrode may comprise two or more electrodes located within different neural structures in the brain.
  • the at least one electrode may comprise two or more electrodes located within different hemispheres of the brain.
  • the processing unit may be further configured to: whilst applying the second stimulus, simultaneously determine one or more second waveform characteristics of the HFOs.
  • the processing unit may be further configured to: compare a common waveform
  • the processing unit may be further configured to: compare a degree of change of a common waveform characteristic between the one or more waveform characteristics and the one or more second waveform characteristics.
  • the processing unit may be further configured to: compare a rate of change of a common waveform characteristic between the one or more waveform characteristics and the one or more second waveform characteristics.
  • the steps of applying the second stimulus whilst simultaneously determining one or more second waveform characteristics of the HFOs may be repeated until it is determined that one or more of the at least one electrode is positioned in a target neural structure in the brain.
  • the processing unit may be further configured to: select one or more of the at least one electrode to use for therapeutic stimulation of a target neural structure in the brain based on the one or more waveform characteristics or the one or more second waveform characteristics; and apply a therapeutic stimulus to the target neural structure via the selected one or more of the at least one electrode.
  • the processing unit may be further configured to: insert the at least one electrode into the brain along a predefined trajectory; wherein the steps of applying the second stimulus whilst simultaneously determining one or more second waveform characteristics of the HFOs are repeated while the at least one electrode is being inserted to generate a profile of HFO activity with respect to the predefined trajectory and a target neural structure in the brain
  • the profile of HFO activity may be used to determine a position of the one or more electrodes relative to the target neural structure.
  • the at least one electrode may comprise a plurality of electrodes.
  • the steps of applying the second stimulus whilst simultaneously determining one or more second waveform characteristics of the HFOs may be repeated using different combinations of the at least one electrode to generate a profile of HFO activity for the different combinations of the at least one electrode.
  • the processing unit may be further configured to: select one or more of the at least one electrode based on the profile of HFO activity; and apply a therapeutic stimulus to the selected one or more of the at least one electrode.
  • the selected one or more of the at least one electrode may comprise a plurality of electrodes.
  • the processing unit may be further configured to:
  • a method for monitoring neural activity responsive to a stimulus in a brain comprising:
  • HFOs high frequency oscillations
  • generating a second stimulus comprising a second plurality of bursts of stimulation, wherein one or more waveform characteristics of the second stimulus is dependent on the one of more waveform characteristics of the HFOs;
  • first plurality of bursts and/or the second plurality of bursts are separated by a first pattern time period, each burst comprising a plurality of pulses separated by a second pattern time period, wherein the first pattern time period is greater than the second pattern time period.
  • two or more of pulses within at least one of the first plurality of bursts have different amplitudes. Additionally or alternatively, two or more of pulses within at least one of the second plurality of bursts have different amplitudes.
  • the different amplitudes may be selected to produce a ramp in amplitude of sequential pulses in the at least one of the bursts of the first plurality of bursts or the second plurality of bursts.
  • the amplitude of a final pulse in each of the first plurality of bursts may be substantially identical. Additionally or alternatively, the amplitude of a final pulse in each of the second plurality of bursts may be substantially identical.
  • a neuromodulation system comprising:
  • a lead having at least one electrode adapted for implantation in or near a target neural structure in the brain;
  • a signal generator selectively coupled to one or more of the at least one electrode and configured to:
  • HFOs high frequency oscillations
  • a processing unit coupled to the measurement device and configured to determine one or more waveform characteristics of the detected HFOs
  • one or more waveform characteristics of the second stimulus is dependent on the one of more waveform characteristics of the HFOs
  • first plurality of bursts and/or the second plurality of bursts are separated by a first pattern time period, each burst comprising a plurality of pulses separated by a second pattern time period, wherein the first pattern time period is greater than the second pattern time period.
  • two or more pulses within at least one of the first plurality of bursts have different amplitudes. Additionally or alternatively, two or more of pulses within at least one of the second plurality of bursts may have different amplitudes.
  • the different amplitudes may be selected to produce a ramp in amplitude of sequential pulses in the at least one of the bursts of the first plurality of bursts or the second plurality of bursts.
  • the amplitude of a final pulse in each of the first plurality of bursts may be substantially identical.
  • the amplitude of a final pulse in each of the second plurality of bursts may be substantially identical.
  • the HFOs being detected may have a frequency of between about 200 Hz and about 350 Hz.
  • the HFOs being detected may have a frequency of between about 230 Hz and about 330 Hz.
  • the HFOs may have a frequency of between about 250 Hz and about 300 Hz.
  • Figure 1 is a graph illustrating resonance from a neural structure responsive to a deep brain stimulation (DBS) signal
  • Figure 2 is a graph illustrating resonance from a neural structure responsive to a patterned DBS signal
  • Figure 3 is a graph illustrating evoked resonance responsive to 10 consecutive pulses of a DBS signal
  • Figure 4 is a graph illustrating the range and variance of peak amplitude of a resonant response to continuous and patterned DBS;
  • Figure 5a is a graphical illustration showing neural resonance evoked by a continuous non- therapeutic patterned DBS signal;
  • Figure 5b is a graphical illustration showing neural resonance evoked by a continuous therapeutic patterned DBS signal
  • Figure 5c is a graphical illustration showing neural resonance after a transition from a continuous therapeutic DBS signal to a non-therapeutic DBS signal
  • Figure 5d is a graph illustrating the estimated frequency of evoked resonance responsive to a non-therapeutic DBS signal
  • Figure 5e is a graph illustrating the estimated frequency of evoked resonance responsive to a therapeutic DBS signal
  • Figure 5f is a graph illustrating the estimated frequency of evoked resonance responsive to a transition between a therapeutic DBS signal and a non-therapeutic DBS signal;
  • Figure 6a is a graphical illustration showing neural resonance evoked by a continuous non- therapeutic patterned DBS signal
  • Figure 6b is a graphical illustration showing neural resonance evoked by a continuous therapeutic patterned DBS signal
  • Figure 6c is a graphical illustration showing neural resonance after a transition from a continuous therapeutic DBS signal to a non-therapeutic DBS signal
  • Figure 6d is a graph illustrating the estimated frequency of evoked resonance responsive to a non-therapeutic DBS signal
  • Figure 6e is a graph illustrating the estimated frequency of evoked resonance responsive to a therapeutic DBS signal
  • Figure 6f is a graph illustrating the estimated frequency of evoked resonance responsive to a transition between a therapeutic DBS signal and a non-therapeutic DBS signal;
  • Figure 7a is a graph illustrating evoked resonances beginning to diverge into two peaks in response to patterned DBS with an amplitude of 1.5mA;
  • Figure 7b is a graph illustrating evoked resonances diverging into two peaks in response to patterned DBS with an amplitude of 2.25mA;
  • Figure 7c is a graph illustrating two separate evoked resonant peaks in response to patterned DBS with an amplitude of 3.375mA;
  • Figures 8a to 8h are spectrograms of high frequency oscillations recorded in a brain during deep brain stimulation
  • Figures 9a to 9h are spectrograms of high frequency oscillations recorded in a brain during deep brain stimulation
  • Figures 10a to lOh are spectrograms of high frequency oscillations recorded in a brain during deep brain stimulation
  • Figure 11 is a schematic illustration of an electrode lead tip for implantation in a brain
  • Figure 12 is a schematic illustration of an electrode lead implanted in the subthalamic nucleus of a brain
  • FIG. 13 is a schematic illustration of a system for administering DBS
  • Figure 14 is a flow diagram illustrating a process for locating a DBS electrode in the brain
  • Figure 15 is a flow diagram illustrating a process for monitoring and processing resonant responses at multiple electrodes in response to stimulation at multiple electrodes;
  • Figure 16 is a graphical illustration of resonant responses measured at different electrodes implanted in a brain responsive to a stimulation signal in accordance with the process shown in Figure
  • Figure 17 is a graphical illustration of resonant responses measured at different electrodes implanted in a brain responsive to stimulation signals applied at different electrodes in accordance with the process shown in Figure 12;
  • Figure 18 is a flow diagram illustrating a process for determining parameters for a DBS stimulation signal based on medicating the patient
  • Figure 19 is a flow diagram illustrating a process for determining parameters for a DBS stimulation signal based on medicating the patient;
  • Figure 20 is a flow diagram illustrating a process for generating a stimulation signal with closed-loop feedback based on evoked resonance at a target neural structure
  • Figure 21 is a flow diagram illustrating a process for generating a stimulation signal with closed-loop feedback based on HFOs from neuronal activity in the brain;
  • Figure 22 is a flow diagram illustrating another process for generating a stimulation signal with closed-loop feedback based on evoked resonance at a target neural structure
  • Figure 23 graphically illustrates switching between periods of therapeutic and non- therapeutic stimulation relative to a resonant activity feature of an evoked response in accordance with the process of Figure 17;
  • Figure 24a illustrates a patterned stimulation signal according to an embodiment of the present disclosure
  • Figure 24b illustrates another patterned stimulation signal according to an embodiment of the present disclosure
  • Figure 25 is a flow diagram illustrating another process for generating a stimulation signal with closed-loop feedback based on HFOs from neuronal activity in the brain.
  • Figure 26 graphically illustrates Washout in the 200-400 Hz washout over consecutive 15 s periods post-DBS and in the last 15 s pre-DBS for 19 brain hemispheres.
  • Embodiments of the present disclosure relate to improvements in neuro-stimulation in the brain.
  • DBS devices typically apply a constant amplitude stimulus to a target area of the brain at a constant frequency of 130 Hz.
  • the inventors have determined not only that application of such a stimulus evokes a neural response from the target area of the brain, but that the neural response comprises a resonant component (evoked resonant neural activity (ERNA)) which has not previously been recognised.
  • ERNA evoked resonant neural activity
  • Continuous DBS at conventional frequencies does not allow a long enough time window to observe the resonant activity. However, by monitoring the neural response after stimulation has ceased (by patterning the stimulation signal or otherwise), the resonant activity can be monitored.
  • Figures 1 to 7c illustrate the effects of patterned and non-patterned stimuli on measured ERNA.
  • HFOs high frequency neural oscillations
  • FIG. 1 graphically illustrates a response from a neural circuit stimulated by a 130 Hz signal delivered from a neurostimulator via an electrode lead, such as the 3387 electrode lead manufactured by Medtronic (RTM), implanted in the subthalamic nucleus (STN) of a Parkinson' s disease (PD) patient.
  • Each response to a stimulus pulse comprises an evoked compound action potential (ECAP) component together with a component of evoked resonant neural activity (ERNA) occurring after the ECAP.
  • ECAP evoked compound action potential
  • ERNA evoked resonant neural activity
  • the ECAP typically occurs within 1-2 milliseconds of the stimulus pulse.
  • the graph shows the response to the last three consecutive pulses of a 60 second period of continuous stimulation followed by a period of no stimulation.
  • the evoked resonant response to each of the first two stimulus pulses shown in Figure 1 is cut short by the onset of the next stimulus pulse, such that only a single secondary peak is detected.
  • the evoked resonant response to the third (and final) pulse is able to resonate for longer and so can be clearly seen in the form of a decaying oscillation with at least seven peaks for a post-stimulus period of about 30 milliseconds.
  • Non-therapeutic stimulation is preferably achieved by administering a stimulus comprising a short burst of pulses followed by a period of no stimulation, and the ERNA is measured during this period of no stimulation.
  • the total charge or energy provided to the patient is below a therapeutic threshold, and the measured ERNA provides information concerning the patient's natural state (without therapy).
  • the overall charge or energy provided to the patient may be reduced by reducing the amplitude of the stimulation signal below a therapeutic threshold. However, doing so may also reduce the amplitude of peaks in the ERNA making it more difficult to observe.
  • patterned stimulation can be used to monitor and analyse evoked resonant neural activity during therapeutic stimulation of a patient.
  • therapeutic stimulation can be maintained whilst providing time windows in which to monitor resonant responses past that of the first resonant peak or more preferably past two or more resonant peaks.
  • FIG. 2 graphically illustrates an example therapeutic patterned DBS stimulus 20 and the associated evoked resonant response according to an embodiment of the present disclosure.
  • the patterned stimulus 20 is shown above the graph to illustrate the correlation between stimulus and response.
  • a single pulse has been omitted from an otherwise continuous 130 Hz pulse train.
  • the pulse train therefore includes a plurality of bursts of pulses of continuous stimulation, each burst separated by a first time period t l5 each of the plurality of pulses separated by a second time period t 2 .
  • Continuation of the stimulus before and after omission of a pulse maintains the therapeutic nature of the DBS, whilst the omission of a pulse allows for resonance of the ERNA to be monitored over several (3 in this example) resonant cycles before the next stimulation pulse interrupts this resonance.
  • stimuli are preferably applied in bursts of multiple pulses, each burst separated by a first time period of no stimulation, each pulse separated by a second time period t 2 .
  • a stimulus signal may comprise a series of 10-pulse bursts at 130 Hz.
  • the multi-pulse burst may be repeated after a predetermined period of no stimulation.
  • the multi-pulse burst may be repeated each second.
  • the duration of the first time period is greater than that of the second time period t 2 .
  • the ratio between the duration of the burst and the duration between bursts may be chosen so as to ensure that relevant properties of the ERNA can be monitored easily and efficiently.
  • the duration of each burst is chosen to be between 1% and 20% of the duration of no stimulation between bursts.
  • the duration of each burst may be chosen to minimise the effects of stimulation on the measured ERNA or to accentuate particular features of the measured ERNA.
  • Figure 3 graphically illustrates how the application of 10 pulses at 130Hz can affect ERNA.
  • the response to the first pulse has a broad, low amplitude first peak.
  • the first peak becomes larger and sharper for subsequent pulses, whilst also shifting to an earlier time.
  • the optimum number of pulses comprised in a burst may be chosen to maximise the amplitude of the resonance, whilst minimizing the time shift of a peak in ERNA across the burst (e.g., the fourth pulse).
  • the rate of change in ERNA features e.g. amplitude, onset delay
  • the rate of change across a burst may be used as a defining characteristic. For example the rate of change across a burst may be used to determine electrode position, optimum parameters, patient state, etc. and/or as a closed loop control signal.
  • burst stimulation provides high amplitude evoked neural responses, making them easier to measure than responses to more continuous DBS.
  • Figure 4 graphically illustrates the range and variance of first peak amplitude of ERNA responsive to more continuous DBS where one pulse is skipped every second (left) and burst DBS (right) (10 pulses only per second). It can be seen that the average peak amplitude of ERNA responsive to burst DBS is around 310 ⁇ whereas the average peak amplitude of ERNA responsive to more continuous DBS is around 140 ⁇ . Further, by using burst stimulation, the evoked resonant response over several oscillatory cycles (20 milliseconds or more) can be monitored.
  • waveform characteristics of the ERNA are dependent on various physiological conditions of the patient. For example, it has been found that therapeutic DBS decreases the frequency of resonance of the target neural circuit.
  • Figures 5a, 5b, and 5c illustrate the variation of frequency of the ERNA during non- therapeutic stimulation (Figure 5a), therapeutic stimulation (Figure 5b), and the ERNA after a transition of stimulation from therapeutic stimulation to non-therapeutic stimulation (Figure 5c).
  • Resonant frequency of the ERNA was measured by calculating the inverse of the time delay between the maxima of two peaks of the ERNA.
  • the resonant frequency may be calculated as an inverse of the average time delay between maxima of all detected peaks of the ERNA.
  • the resonant frequency may be calculated by fitting a damped oscillator model to the resonant activity and extracting the natural frequency or by performing spectral analyses (e.g. Fourier transform, wavelet transform). Other techniques for frequency estimation, such as estimating the time between zero-crossings in the waveform or using other features of the waveform may also be used for this purpose.
  • a patterned stimulus was administered to the patient in the same manner as described with reference to Figures 1 and 2.
  • Figures 5a and 5b show the responses to a patterned non-therapeutic and therapeutic DBS stimulation, respectively.
  • non- therapeutic stimulation consisted of bursts of 10 pulses delivered at a frequency of 130 Hz over a 1- second time period with the remaining 120 pulses (which would be present during continuous stimulation) skipped.
  • the typical observable window of the response is denoted by the horizontal dotted line.
  • the amplitude of pulses may be modulated over time, including applying a ramp to increase the pulse amplitudes over several pulses within a burst and/or a ramp to decrease the pulse amplitudes over several pulses within a burst.
  • a ramp to increase the pulse amplitudes over several pulses within a burst and/or a ramp to decrease the pulse amplitudes over several pulses within a burst.
  • Figure 5c shows the responses after switching back to the non-therapeutic patterned stimulation.
  • the therapeutic effect of the patterned therapeutic stimulus 'washes out' and the ERNA returns to its baseline state.
  • the first peak of resonant activity across all conditions typically all that can be measured using conventional continuous DBS
  • characteristics of subsequent parts of the ERNA waveform, made measurable by patterning the stimulation exhibit much larger changes in frequency and amplitude. Monitoring of the response over a longer period therefore enables information concerning frequency, amplitude, envelope, and fine structure of the time-varying oscillation to be analysed.
  • Figure 5d shows the resonant frequency of the ERNA during periods of non-therapeutic stimulation to be around 400-450 Hz.
  • Clinically effective stimulation reduces the frequency of the ERNA to around 300-350 Hz as shown in Figure 5e.
  • Figure 5f illustrates the transition of resonant frequency from 300-350 Hz back to around 400-450 Hz after therapeutic stimulation has been replaced with non-therapeutic stimulation.
  • Figures 6a, 6b, and 6c illustrate another example from a different patient of the variation of the ERNA during non-therapeutic patterned stimulation (Figure 6a), therapeutic patterned stimulation (Figure 6b) and the ERNA after a transition from therapeutic stimulation to non-therapeutic stimulation ( Figure 6c).
  • patterned stimuli were administered to the patient in the same manner as described with reference to Figures 5a to 5e.
  • the initial non-therapeutic stimulation ( Figure 6a) does not cause noticeable changes to the ERNA and that the therapeutic stimulation (Figure 6b) causes a reduction in the frequency of the resonance, which returns to baseline levels after the stimuli is transitioned back to non-therapeutic patterned stimulation ( Figure 6c).
  • the change in resonant frequency with therapeutic stimulation is accompanied by an increase in the delay between each stimulus pulse and the onset of the resonance.
  • This increase in onset delay shifts the second resonant peak such that it occurs outside the typical observable window for conventional (non-patterned) DBS.
  • the measurement window is made long enough to observe three resonant peaks, allowing ERNA to be characterised.
  • the amplitude of the resonance is decreased by therapeutic stimulation.
  • Figures 6d, 6e, and 6f further illustrate the reduction in resonant frequency with therapeutic stimulation in this example.
  • Resonant frequency was estimated by calculating the inverse of the time delay between the maxima of two peaks of the ERNA.
  • the frequency of the ERNA measured using non-therapeutic patterned stimulation can be seen to be about 350Hz.
  • the application of therapeutic patterned stimulation in Figure 6e causes the frequency to decrease to around 250Hz.
  • the frequency can be seen to be returning to its baseline level in Figure 6f after transitioning back to non-therapeutic patterned stimulation.
  • Figures 7a, 7b and 7c illustrate ERNA in response to continuous DBS at 1.5 mA, 2.25 mA and 3.375 mA respectively.
  • the resonant ERNA starts as a single peak, which can be seen to begin to diverge slightly into two peaks.
  • the dominance switches to the later of the two peaks.
  • the earlier peak which was dominant at 1.5 mA, continues at a lower amplitude.
  • two peaks are present, with the later peak dominating. It is thought that these multiple resonant peaks correspond to activity in different neural circuits.
  • the relative amplitude between these resonant responses may be an indicator of therapeutic state.
  • DBS can affect spontaneous neuronal activity in the brain, in particular high frequency oscillations (HFOs) which can be measured in local field potentials (LFPs).
  • HFOs high frequency oscillations
  • LFPs local field potentials
  • the inventors have realised that artefacts in recorded local field potentials can be reduced by manipulating characteristics of the DBS stimulation waveform without affecting patient therapy administered using DBS.
  • charge associated with the longer duration low-amplitude portion of an asymmetric stimulus couples to the apparatus used to process electrical signals received from recording electrodes.
  • this charge coupling causes recording amplifier(s) to operate in a non-linear state, which results in inaccurate measurements and the aforementioned artefacts.
  • the inventors have found that by using a symmetric DBS stimulus, they are able to reduce instances of charge coupling so as to increase the visibility of HFOs in local field potentials. Whilst less ideal, a similar affect may also be achieved by using a biphasic stimulation waveform having a first phase at a first amplitude for a first duration and a second phase of opposite polarity to the first phase, the second phase having a second amplitude and a second duration, the product of the first amplitude and the first duration being substantially equal to the product of the second amplitude and the second duration. In doing so, the charge of the first and second phases of the waveform are equal and opposite.
  • a biphasic stimulation waveform may be used in which the second phase was half the amplitude and double the duration of the first phase. In another embodiment, a biphasic stimulation waveform may be used in which the second phase was a third the amplitude and triple the duration of the first phase.
  • patterned DBS stimulation can be used to enhance the visibility of HFOs so that they can be used to set DBS stimulation parameters, guide the placement of DBS electrodes, track therapy and disease progression, and help with control of closed loops DBS stimulation.
  • HFO characteristic frequency This frequency to which HFO activity trends will herein by referred to as the HFO characteristic frequency.
  • Figures 8a to 8h illustrate this activity by way of a series of spectrograms which show the effect of varying DBS stimulus amplitude on measured HFO frequency.
  • a patient was stimulated by a 130 Hz pulse train comprising biphasic symmetric pulse waveforms delivered from a neurostimulator via an electrode lead, such as the 3387 electrode lead manufactured by Medtronic (RTM), implanted in the subthalamic nucleus (STN) of the patient.
  • the pulse width was 60 ⁇ 8 per phase.
  • the amplitude of the stimulus was varied in a stepwise manner between 0 A and 3.375 mA as denoted at the top of each spectrogram.
  • a very short gap in stimulation (period of zero stimulation) of approximately 1 second was present in the stimulus between each amplitude condition.
  • the vertical axis corresponds to frequency in hertz and the horizontal axis corresponds to time in seconds.
  • Measured local field potentials which include HFOs, are depicted in lighter shades in each spectrogram. The whiter the shade, the stronger the signal received at electrodes at a particular frequency and time.
  • Figures 8a is a spectrogram showing measured local field potentials during periods of zero stimulation (HFO activity across a frequency range in hertz over time in seconds,.
  • Figures 8b and 8h are spectrograms showing HFO activity during non-therapeutic patterned DBS.
  • Figures 8c to 8g are spectrograms showing HFO activity during therapeutic DBS.
  • Figures 8c to 8g show that the rate of change of frequency of recorded HFO activity increases with increasing amplitude, suggesting that higher amplitude DBS causes HFO activity to reach its final frequency more quickly.
  • Figure 8g shows that when DBS amplitude increases beyond a threshold, HFO activity is supressed when compared with HFO activity at lower DBS amplitudes (e.g. Figures 8c and 8d). This is exemplified in Figure 8g, which shows that HFO activity during stimulation at 3.375 mA reduces visibility of HFO activity.
  • This data can be used to identify optimal stimulation amplitudes for therapy.
  • the amplitude can be chosen to be high enough to steady HFOs at the HFO characteristic frequency but not so as high as to suppress HFOs.
  • HFO characteristic frequency of 260 Hz is a harmonic (x2) of the default DBS rate (130 Hz) that has been found to be effective in a large proportion of patients undergoing conventional DBS therapy. It is noted, however, that the default 130 Hz DBS rate is not the optimum stimulation rate for all patients undergoing DBS therapy. In some instances, DBS therapy at 130 Hz is, in fact, detrimental. The inventors have realised that this is likely due to a variation of HFO characteristic frequency between patients. For example, whilst a large proportion of patients may exhibit an HFO characteristic frequency of around 260 Hz, some patients may exhibit a different HFO characteristic frequency indicating that a different DBS rate would be more effective in their therapy. Accordingly, measurements of HFOs taken in accordance with Figures 8a to 8g may be used to identify a characteristic frequency associated with a patient, which in turn may be used to determine an optimum frequency for DBS therapy.
  • Figures 9a to 9h which depict HFO activity across a frequency range (in Hz) over time (in seconds), provide a further example of the effect of DBS amplitude on HFO activity in a different patient.
  • HFO activity is driven to a HFO characteristic frequency of around 280 Hz which is different to the HFO
  • the HFO characteristic frequency of the patient whose HFO activity is shown in Figures 8a to 8h is patient specific and can vary widely (typically between 200Hz and 350 Hz). As previously stated, this suggests that there is a patient specific frequency at which the aggregate neuronal brain activity of a patient oscillates during DBS and that it may be preferable to adjust DBS rate to correlate with this HFO characteristic frequency.
  • HFO activity can also be used to identify optimum stimulation frequencies for therapy.
  • FIGS 10a to lOj are spectrograms of HFOs measured in local field activity for a patient being administered with DBS at varying frequencies of stimulation (zero stimulation in the case of Figure 10a). These results are taken from measurements of a different patient to those of Figures 8 and 9. For each frequency of stimulation, it can be seen that at the onset of stimulation, HFO activity is centred at a different frequency which seems to be related approximately to the frequency of DBS. However, after a period of time (within approx. 100 s) in each case the frequency of HFO activity tends to the same HFO characteristic frequency; around 260 Hz.
  • the most effective DBS rate for therapeutic treatment of the patient to which Figures 10a to lOj relate was found to be 130 Hz, which again is half of the measured HFO characteristic frequency. This again suggests that the HFO characteristic frequency of a patient relates to the most effective DBS frequency for patient therapy.
  • one or more electrode leads may be used for stimulation of one or more neural structures within one or both hemispheres of the brain, each lead comprising one or more electrodes located near the tip of each lead.
  • Each of the electrodes may be used for stimulation, monitoring, or both stimulation and monitoring.
  • One or more of these electrodes may be implanted. Implanted electrodes may be used independently or in addition to one or more electrodes placed on the outside of the brain or skull.
  • a typical DBS electrode lead tip 70 such as that incorporated into the Medtronic (RTM) DBS Lead Model 3387, is shown in Figure 11.
  • the lead tip 70 comprises a first electrode 72a, a second electrode 72b, a third electrode 72c, and a fourth electrode 72d.
  • each of the electrodes 72a, 72b, 72c, 72d may be used to apply a stimulus to one or more neural structures or monitor and optionally record the evoked response (including ERNA) from neural circuits to the stimulus and the HFO activity measured from local field potentials in the brain.
  • leads with more electrodes or electrodes with different sizes or topologies may be used.
  • one or more reference electrodes may be located at a remote site and used to complete the electrical circuit when one or more electrodes on the DBS lead are activated for stimulation or used for signal monitoring.
  • the target location for the lead tip 70 varies dependent on the neural structure.
  • Example target structures include but are not limited to the subthalamic nucleus (STN), the substantia nigra pars reticulata (SNr), and the globus pallidus interna (GPi).
  • Figure 12 shows the lead tip 70 implanted into a brain at a target structure, in this case the subthalamic nucleus (STN) 82.
  • STN subthalamic nucleus
  • the accuracy of locating electrodes of the electrode tip 70 within a target structure can be greatly increased by using a series of patterned stimulations to generate and measure an evoked resonant response from a neural target.
  • Such techniques can obviate the need for the patient to be awake during the implantation procedure, since an electrode can be located much more accurately at the correct location within the brain and relative to a target neural structure. This means that patients can be under sedation or general anaesthetic during the surgery since no patient feedback is required to locate the electrode to a satisfactory degree of accuracy.
  • FIG. 13 An example DBS delivery system 90 according to an embodiment of the present disclosure is illustrated in Figure 13.
  • the system 90 comprises the lead tip 70 of Figure 11 including the plurality of integrated electrodes 72a, 72b, 72c, 72d, together with a processing unit 92, a signal generator 94, a measurement circuit 96 and an optional multiplexer 98.
  • the processing unit comprises a central processing unit (CPU) 100, memory 102, and an input/output (I/O) bus 104 communicatively coupled with one or more of the CPU 100 and memory 102.
  • CPU central processing unit
  • I/O input/output
  • the multiplexer 98 is provided to control whether the electrodes 72a, 72b, 72c, 72d are connected to the signal generator 94 and/or to the measurement circuit 96. In other embodiments the multiplexer may not be required. For example, the electrodes 72a, 72b, 72c, 72d may instead be connected directly to both the signal generator 94 and the measurement circuit 96. Although in Figure 13 all of the electrodes 72a, 72b, 72c, 72d are connected to the multiplexer 98, in other embodiments, only one or some of the electrodes 72a, 72b, 72c, 72d may be connected.
  • the measurement circuit 96 may include one or more amplifiers and digital signal processing circuitry including but not limited to sampling circuits for measuring neural responses to stimulation, including ERNA. In some embodiments the measurement circuit 96 may also be configured to extract other information from received signals, including local field potentials for measurement of HFOs and the like. The measurement circuit 96 may also be used in conjunction with the signal generator 94 to measure electrode impedances. The measurement circuit 96 may be external to or integrated within the processing unit 92. Communication between the measurement circuit 96 and/or the signal generator 94 on the one hand and the I/O port on the other may be wired or may be via a wireless link, such as over inductive coupling, WiFi (RTM), Bluetooth (RTM) or the like. Power may be supplied to the system 90 via at least one power source 106. The power source 106 may comprise a battery such that elements of the system 90 can maintain power when implanted into a patient.
  • the signal generator 94 is coupled via the multiplexer 98 to one or more of the electrodes 72a, 72b, 72c, 72d and is operable to deliver electrical stimuli to respective electrodes based on signals received from the processing unit 92. To this end, the signal generator 94, the multiplexer 98 and the processing unit 92 are also communicatively coupled such that information can be transferred therebetween.
  • signal generator 94 Whilst the signal generator 94, multiplexer 98, and the processing unit 92 in Figure 13 are shown as separate units, in other embodiments the signal generator 94 and multiplexer may be integrated into the processing unit 92. Furthermore, either unit may be implanted or located outside the patient's body.
  • the system 90 may further comprise one or more input devices 108 and one or more output devices 110.
  • Input devices 108 may include but are not limited to one or more of a keyboard, mouse, touchpad and touchscreen. Examples of output devices include displays, touchscreens, light indicators (LEDs), sound generators and haptic generators.
  • Input and/or output devices 108, 110 may be configured to provide feedback (e.g. visual, auditory or haptic feedback) to a user related, for example, to characteristics of ERNA or subsequently derived indicators (such as proximity of the electrode 70 relative to neural structures in the brain.
  • feedback e.g. visual, auditory or haptic feedback
  • one or more of the input devices 108 may also be an output device 110, e.g. a touchscreen or haptic joystick.
  • Input and output devices 108, 110 may also be wired or wirelessly connected to the processing unit 92. Input and output devices 108, 110 may be configured to provide the patient with control of the device (i.e. a patient controller) or to allow clinicians to program stimulation settings, and receive feedback of the effects of stimulation parameters on ERNA and/or HFO characteristics.
  • One or more elements of the system 90 may be portable. One or more elements may be implantable into the patient.
  • the signal generator 94 and lead 70 may be implantable into the patient and the processing unit 92 may be external to the patient's skin and may be configured for wireless communication with the signal generator via RF transmission (e.g. induction, Bluetooth (RTM), etc.).
  • RF transmission e.g. induction, Bluetooth (RTM), etc.
  • the processing unit 92, signal generator 94 and lead 70 may all be implanted within the patient's body.
  • the signal generator 94 and/or the processing unit 92 may be configured to wirelessly communicate with a controller (not shown) located external to the patient's body.
  • One embodiment of the present disclosure provides a system and method for localising the lead tip 70 within a target structure of the brain using measured ERNA and/or HFO activity.
  • the system 90 may be used to provide real-time feedback to the surgeon based on characteristics such as the strength and quality of evoked response signals received from one or more electrodes of the lead tip 70. This feedback may be used to estimate position within the target structure in three dimensions and to inform the decision of whether to reposition the electrodes or remove and reimplant the electrodes along a different trajectory.
  • FIG 14 shows a general example of such a process.
  • the process begins at step 112 with an electrode lead tip such as that described with reference to Figure 11 being advanced during surgery towards a target neural structure along a predefined trajectory.
  • the step size (or spatial resolution) by which the electrode lead is advanced may be chosen by the surgeons and/or clinicians. In some embodiments, the step size is 1 mm.
  • evoked responses, including ERNA are measured by applying a patterned stimulus such as those described above to an electrode of the lead tip 70. The stimulus may be applied for the whole time whilst the lead tip 70 is being implanted. Alternatively, the patterned signal may be repeated a predetermined number of times, such as 10 times.
  • the evoked response may be measured at the same electrode as that used to apply the stimulus or may be measured at one or more different electrodes. By doing so, a more accurate estimate of the location of each electrode relative to the target neural structure may be provided. Steps 112 and 114 are repeated until the electrode lead tip has been inserted to the maximum allowable depth, which may be in the target neural structure or slightly beyond it.
  • a profile or map of evoked responses at different locations along the insertion trajectory may be generated.
  • the profile of evoked responses may include measurements from multiple electrodes or from just one electrode.
  • the profile of evoked responses at different depths may be output to the one or more output devices 110.
  • the profiles of evoked responses are then compared at step 118 in order to determine whether a preferred electrode location can be identified.
  • the identification of preferred electrode location may be based on different ERNA features, including relative differences between or spatial derivatives of amplitude, rate of decay, rate of change, and frequency, at different insertion positions (e.g. the location that produces the largest resonances).
  • the identification of a preferred electrode location may also be based on comparison with template ERNA activity, where the templates have been derived from recordings from other patients.
  • the profile of evoked responses may also be used to estimate the trajectory of the electrode lead 70 through the target neural structure, including the boundaries of the structure and the region intersected (e.g. the trajectory passed through the medial or lateral region).
  • the profile of evoked responses may also be used to estimate the proximity to the target structure, in the event that the target structure is not intersected by the insertion trajectory.
  • the electrode lead tip 70 can be repositioned at step 122, such that an electrode is positioned at the preferred location.
  • the electrode positioned closest to the preferred location can be nominated for subsequent use in applying therapeutic stimulation. If at step 120 a preferred location cannot be identified, the surgeon and/or clinician may choose to remove the electrode and re-implant along a different trajectory.
  • Another embodiment of the present disclosure provides a system and method for determining the relative positions of an array of electrodes with respect to a target neural structure and then selecting a preferred electrode to use for applying therapeutic stimulation. This process could be performed during electrode implantation surgery to assist in the positioning of electrodes, or with previously implanted electrodes when programming the device to deliver therapeutic stimulation.
  • a stimulus may be applied at more than one of the electrodes of the array, for example two or more of electrodes 72a, 72b, 72c, 72d in the case of electrode array 70. Where a patterned stimulation regime is used, sequential bursts of a stimulus pattern may be applied to different ones of the electrodes 72a, 72b, 72c, 72d.
  • a full stimulus pattern may be applied at one electrode, followed by another full stimulus pattern at another electrode.
  • a determination may be made concerning which electrode of an electrode array is positioned best to provide therapeutic stimulation to one or more of the target neural structures; for example, which of the electrodes 72a, 72b, 72c, 72d is best positioned within a target neural structure.
  • FIG. 15 illustrates an example process 130 for measuring evoked response from an array of multiple electrodes.
  • a stimulus is applied to the first electrode of an array of X electrodes (electrode 72a in the case of the lead tip 70).
  • the stimulus applied may be a burst patterned stimulus as described above.
  • the evoked response from a target neural structure is measured at one or more of the electrodes in the array at step 134.
  • the evoked response may be measured at the second, third and fourth electrodes 72b, 72c, 72d when the first electrode 72a is being stimulated.
  • the evoked responses received at the stimulating electrode may also be recorded and optionally stored in memory.
  • step 138 After the process has checked at step 136 to see whether all electrodes in the array of X electrodes have been stimulated, i.e. whether the process has cycled through all of the electrodes in the system. If there are electrodes remaining to be stimulated, then the process repeats, applying a stimulus to the next selected electrode in the array. If all electrodes in the array have been stimulated and an evoked response to stimulation at each electrode measured and recorded, the resultant measured evoked responses are then processed at step 140.
  • Processing the evoked responses may involve comparing different ERNA features, including relative differences between or spatial derivatives of amplitude, rate of decay, rate of change, and frequency, across different combinations of electrodes used for stimulation and measurement. For example, the processing may involve identifying the electrode that measures the largest evoked resonance amplitude for each stimulation condition). The identification of the preferred electrode location may also be based on a comparison with template ERNA activity. Templates may be derived from recordings from other patients or from one or more models or simulations.
  • a preferred electrode to use for therapeutic stimulation may be chosen at step 142.
  • the results of the ERNA processing and a recommendation for the preferred electrode may be output to the one or more output devices 110. If the process has been performed during surgery, the results of the ERNA processing may also be used to determine which electrodes are within the target neural structure and whether to reposition the electrode array. The results may also be used to generate one or more templates for future processing of evoked responses in the same or different patients.
  • Figure 16 shows an example of the evoked responses measured at each of the first, second and fourth electrodes 72a, 72b, 72d based on patterned stimulation applied to the third electrode 72c. This example corresponds to one iteration of steps 132 and 134 of process 130 shown in Figure 15.
  • the stimulated electrode 72c is represented with the crossed axes. Firstly, it is shown that a resonant response over several cycles can be measured using the novel patterned stimulus.
  • the response at the second electrode 72b has the largest amplitude
  • the amplitude of response at the fourth electrode 72d has the smallest amplitude
  • the amplitude of the evoked response at the first electrode 72a is substantially less than that at the second electrode 72b but slightly greater than that at the fourth electrode 72d.
  • the evoked response is measured at three electrodes, in other embodiments, the evoked response may be measured at one or two or any number of electrodes in any configuration.
  • ERNA could be measured and/or recorded from different combinations of electrodes.
  • measurement electrodes may be implanted in and/or positioned external to the brain or skull.
  • FIG. 17 graphically illustrates example evoked responses to stimulation in accordance with the process 130 of Figure 15 applied to the lead tip 70 of the system 90 shown in Figure 13.
  • Each column of graphs represents one of four stimulation conditions with the stimulated electrode represented by the crossed panel, i.e. each column is an iteration of steps 132 and 134 of process 130.
  • the data shown in Figure 17 was measured with the second and third electrodes 72c, 72d positioned within the subthalamic nucleus (STN) of a patient's brain. It can be seen that the largest evoked responses are observed at each of the second and third electrodes 72b, 72c when the other of those electrodes 72c, 72b is stimulated.
  • STN subthalamic nucleus
  • a determination can be made firstly of whether any of the electrodes are positioned within the target neural structure, secondly whether any of the electrodes are positioned at an optimum location within the target neural structure, and thirdly the direction and/or distance of a particular electrode from that target neural structure.
  • one or more of the presence, amplitude, natural frequency, damping, rate of change, envelope, and fine structure of an evoked resonant response to a stimulus may be used to identify the most effective electrode in an electrode array.
  • the evoked responses vary depending on the position of the electrode used for stimulation, illustrating the feasibility of using the process illustrated in Figure 14 to localise electrodes within a target neural structure.
  • the process 130 of Figure 15 may be repeated using different stimulation parameters (e.g. using different stimulation amplitudes or frequencies) or with more than one stimulating electrode in step 132 (e.g. stimulation applied concurrently through multiple electrodes on one or more electrode leads).
  • the response characteristics obtained may be used to aid current steering (e.g. setting the distribution of currents across electrodes that are active simultaneously) and the selection of active electrodes (e.g. which electrodes to use for stimulation). For example, response characteristics can be used to estimate the spatial spread of activation relative to the target area.
  • the stimulation profile may be shaped using two or more electrodes to direct stimulation to particular areas of the brain, i.e. towards a target structure, and away from areas which the clinician does not wish to stimulate.
  • both ERNA and HFO activity can be used to optimize stimulation parameters used to target various medical conditions. For instance, once an electrode array such as the lead tip 70 has been accurately located within a target neural structure, the setting of stimulation parameters for therapeutic DBS can be aided by measuring ERNA and/or HFO activity, improving accuracy and time- and cost-efficiency, and reducing undesirable side -effects.
  • the change in elicited resonant activity and the measurement of HFO activity in local field potentials for different stimulation parameters may be used to optimize stimulation settings. Such processes can enable therapy to be tailored to the individual needs of patients and can be performed with minimal clinical intervention.
  • one or more of the presence, amplitude, natural frequency, damping, rate of change, envelope, and fine structure of an evoked resonant response to a stimulus may be used to optimise stimulation.
  • one or more of the presence, amplitude, frequency, damping, rate of change, envelope, and fine structure of an HFO measured in local field potentials during DBS stimulation may be used to optimise stimulation.
  • Such response characteristics and HFO characteristics may be used to adjust amplitude, frequency, pulse width, and shape of a stimulation waveform.
  • a parameter of therapeutic stimulation that is particularly difficult to set using state of the art techniques is stimulation frequency. This is partly because optimum stimulation frequency can vary from patient to patient; typically between around 90 Hz to around 185 Hz.
  • one or more of the above described characteristics of ERNA and/or HFO activity may be used to set frequency of stimulation (e.g. the time period t 2 between pulses in a burst).
  • the stimulation frequency might be selected to approximate a multiple or submultiple of a frequency component of the ERNA, such as the estimated fundamental frequency of the ERNA.
  • the stimulation frequency can be selected to be dependent on a characteristic of the measured HFO activity, such as the HFO characteristic frequency.
  • the stimulation frequency may be selected to be half of a measured HFO characteristic frequency of a patient.
  • optimisation techniques such as machine learning or particle swarm may be implemented to find an optimal set of parameter values within the multidimensional parameter space. Such techniques may involve an iterative process of trying a selection of different parameter settings to determine the most effective parameter values based on the monitored ERNA and/or HFO activity.
  • ERNA and/or HFO activity monitoring and DBS parameter optimisation can be performed on a patient before and after administration of medication for relieving symptoms of a condition.
  • a record of ERNA for a particular patient who is on or off such medication may be used as a benchmark for an evoked resonant response which provides the most benefit to a patient so that parameters can be tuned to try to replicate such evoked response states.
  • a record of HFO activity for a particular patient who is on or off such medication may be used as a benchmark for HFO activity which correlates with the most benefit to a patient so that parameters can be tuned to try to replicate such HFO activity.
  • FIG 18 schematically illustrates a method of determining stimulation parameters based on the ERNA responsive to the stimulation of a medicated patient.
  • a stimulus is applied to an implanted electrode in a target neural structure of a patient before being administered with any medication, and the ERNA from the stimulus is measured and recorded at step 146.
  • the patient is then medicated at step 148.
  • a clinician may administer a dose of a drug (e.g., levodopa) to the patient.
  • steps 150 and 152 the process of stimulation and measurement of resonant response are repeated.
  • the ERNA before and after the medicament is administered is then used to determine stimulation parameters which approximate those of the patient's medicated state.
  • DBS parameter settings may be chosen which, when administered, replicate or approximate the transition from the uncontrolled-symptom ERNA to the controlled-symptom ERNA.
  • FIG 19 schematically illustrates a method of determining stimulation parameters based on the HFO activity responsive to the stimulation of a medicated patient.
  • a stimulus is applied to an implanted electrode in a target neural structure of a patient before being administered with any medication, and the HFO activity from the stimulus is measured and recorded at step 149.
  • the patient is then medicated at step 151.
  • a clinician may administer a dose of a drug (e.g., levodopa) to the patient.
  • steps 153 and 155 the process of stimulation and measurement of resonant response are repeated.
  • the HFO activity before and after the medicament is administered are then used to determine stimulation parameters which approximate those of the patient's medicated state.
  • DBS parameter settings may be chosen which, when administered, replicate or approximate the transition from the uncontrolled-symptom HFO activity to the controlled-symptom HFO activity.
  • optimisation processes may be performed by a clinician when the system 90 is being installed or during a visit to a healthcare centre. Additionally or alternatively, the optimisation may be run by the patient or may be instigated by the system 90 automatically. For example, the system 90 may implement an optimisation process periodically (e.g. every day, week or month). In other embodiments, an optimisation process could be initiated on replacement or recharge of a battery, in circumstances where the power source 106 includes a battery. Other conditions that could trigger an optimisation process include a change in the patient's state, such as whether the patient is engaged in a fine motor task, a gross motor task, speaking, sleeping, or is sedentary.
  • the system 90 may store a series of previously optimised settings in the memory 102. These stored settings may correspond to the optimised settings for different patient states (e.g. fine or gross motor activation, sleeping or sedentary) and may include stimulation being applied to different target neural structures.
  • the patient may be given the ability to choose which of the stored stimulation settings they want to use at any given time, through the use of a patient controller.
  • the system 90 may automatically choose which of the stored stimulation settings to use based on measurements of the patients state from electrophysiological signals (e.g. ERNA or local field potentials (e.g. HFO activity)) recorded from the electrodes 70 by system 90 or from measurements taken with input devices 108 of the system 90 (e.g. accelerometers).
  • electrophysiological signals e.g. ERNA or local field potentials (e.g. HFO activity)
  • ERNA and HFO activity may be used to generate feedback for controlling the stimulation of electrodes.
  • feedback may be implemented using the system 90 shown in Figure 13.
  • the system 90 may use a waveform template corresponding to a preferred patient state.
  • the template may be generated using previous recordings of ERNA and/or HFO activity in a patient with reduced symptoms.
  • ERNA/HFO templates recorded from a medicated patient or a patient receiving effective stimulation treatment may be used.
  • ERNA/HFO templates recorded from a healthy patient, e.g. a patient without a movement disorder, may be used. Templates may be constructed from the average of many recordings from one patient or several patients.
  • selected features of the ERNA waveform and/or the HFO activity waveform may be used instead of a complete template.
  • parameters of the ERNA such as the dominant frequency and amplitude components and/or temporal features may be used to enable improved electrode placement and control of therapeutic stimulation.
  • parameters of HFO such as characteristic frequency and amplitude components may be used to enable improved electrode placement and control of therapeutic stimulation.
  • preferred ranges for different ERNA characteristics may be defined (e.g. stimulation is controlled such that the ERNA frequency remains within 250-270Hz).
  • parameters of the HFO activity such as HFO characteristic frequency and amplitude components and/or temporal features may be used in the control of therapeutic stimulation.
  • preferred ranges for different HFO activity may be defined (e.g. stimulation is controlled such that the HFO frequency trends to 260 Hz, or such that rate of change of HFO frequency to characteristic frequency is greater than a predetermined threshold rate).
  • the processing unit 92 may send instructions/signals to the signal generator 94 to generate a stimulation signal, such as a patterned stimulation signal, which may or may not have been pre-calibrated in accordance with an embodiment described above.
  • the signal generator 94 may then generate the signal at step 160 and apply it to one of the electrodes 72a, 72b, 72c, 72d of the lead tip 70 (step 162).
  • the processing unit 92 may then measure the ERNA and monitor one or more parameters (or characteristics) of the ERNA (step 164).
  • the processing unit 92 may then process the received ERNA data (step 166).
  • the processing unit 92 may compare the ERNA (or one more parameters thereof) with a resonant response associated with effective therapy (or one or more parameters thereof). Based on the ERNA data, the processing unit 92 may then instruct the signal generator to adjust one or more parameters of the stimulation signal applied to one of the electrodes 72a, 72b, 72c, 72d (step 168).
  • the processing unit 92 may send instructions/signals to the signal generator 94 to generate a stimulation signal, such as a patterned stimulation signal, which may or may not have been pre-calibrated in accordance with an embodiment described above.
  • the signal generator 94 may then generate the signal at step 161 and apply it to one of the electrodes 72a, 72b, 72c, 72d of the lead tip 70 (step 163).
  • the processing unit 92 may then measure the HFO activity and monitor one or more parameters (or characteristics) of the HFO activity (step 165).
  • the processing unit 92 may then process the received HFO activity data (step 167).
  • the processing unit 92 may compare the HFO activity (or one or more parameters thereof) with HFO activity associated with effective therapy (or one or more parameters thereof). Based on the HFO activity data, the processing unit 92 may then instruct the signal generator to adjust one or more parameters of the stimulation signal applied to one or more of the electrodes 72a, 72b, 72c, 72d (step 169).
  • the signal applied at step 161 may comprise multiple components each having a different frequency.
  • the signal may increase stepwise in frequency (e.g., 120 Hz, 130 Hz, 140 Hz, 150 Hz etc.).
  • the multiple components of the signal applied at step 161 may each have a different amplitude.
  • the amplitude of the signal may increase stepwise in amplitude between components (e.g., 1 mA, 2 mA, 3 niA etc.).
  • the processing unit 92 may, at step 167, identity the HFO characteristic frequency of the HFO activity, i.e. the frequency to which the HFO activity is driven over time in the presence of the signal applied at step 161.
  • the signal may be adjusted so as to set the stimulation rate for therapy in dependence of the HFO characteristic frequency.
  • the stimulation rate may be chosen to be a sub-multiple of the HFO characteristic frequency (e.g., c l * f H Fo/2, fHFo/3 etc.), and preferably to a sub-multiple of half the HFO characteristic frequency.
  • the processing unit 92 may, at step 167, identify amplitudes of the applied signal at which HFO activity is promoted, driven to a particular frequency, and/or supressed.
  • the amplitude of the signal may then be adjusted, for example, to the lowest that achieves the desired HFO activity effects. Desired effects may be compared with one or more templates as described above.
  • bursts of stimulation in combination with the monitoring of ERNA and/or HFO activity may be used to identify a therapeutic resonant state (e.g. a state which correlates with good symptom suppression with minimal side effects and/or minimum electrical power consumption). From this information, therapeutic stimulation parameters required to produce the preferred therapeutic state may be identified. In some embodiments, these stimulation parameters may be used to apply continuous therapeutic DBS to the target neural structure.
  • Probe bursts for identifying resonant activity can be interleaved with the therapeutic DBS to re-assess the resonant state as well as HFO activity. These probe bursts may be implemented on a periodic basis, for example, every 10 seconds. In one embodiment, every 10 seconds, a probe burst may be applied for 1 second (e.g. 10 pulses at 130 Hz) and the ERNA and/or HFOs assessed. The therapeutic stimulation parameters may then be adjusted or maintained based on the ERNA and/or HFOs.
  • the stimulation parameters may be adjusted such that the ERNA becomes comparable with the previously measured ERNA and/or the template ERNA and/or an ERNA characteristic is within a desired range.
  • the stimulation parameters may be adjusted such that the becomes comparable with the previously measured HFO activity and/or the template HFO and/or a HFO characteristic which is within a desired range.
  • the therapeutic stimulation may be adjusted based on the measured ERNA.
  • the resonant circuit if the resonant circuit is in a preferred resonant state, e.g. if the measured ERNA substantially matches a template or if an ERNA characteristic is within a desired range, the amplitude of the therapeutic stimulation may be reduced by the signal generator 94 in response to an instruction from the processing unit 92. Conversely, if the neural circuit is not in a preferred resonant state, the amplitude of therapeutic stimulation may be increased by the signal generator 94.
  • the DBS stimulation may be switched off altogether or until after the next probe burst is applied to generate a measurable ERNA. Then when the next probe burst is applied, if the resonance is no longer therapeutic, the DBS stimulation may be switched back on.
  • the DBS stimulation may be switched off altogether or until after the next probe burst is applied to generate a measurable ERNA. Then when the next probe burst is applied, if the resonance is no longer therapeutic, the DBS stimulation may be switched back on.
  • the length of continuous stimulation blocks (between probe bursts) and the duration of the probe bursts may be adjusted to optimise the ERNA and/or HFO activity. Longer continuous stimulation periods or blocks between probe bursts will reduce the computation load on the processing unit 92 and thus increase power efficiency but may also result in greater variation of ERNA and/or HFOs from the preferred ERNA and/or HFOs and thus a reduction in effectiveness of treatment.
  • burst stimulation for identifying a therapeutic DBS state has been described in connection with ERNA.
  • short bursts of stimulation like those described above in relation to ERNA
  • bursts can, therefore, be used to elevate HFO power to measureable levels, allowing them to be evaluated without the need for simultaneous therapeutic DBS.
  • bursts of stimulation can also be used in combination with the monitoring of HFO activity in several ways.
  • enhanced HFO activity can be used in the identification of a therapeutic DBS state (e.g. a state which correlates with good symptom suppression with minimal side effects and/or minimum electrical power consumption).
  • therapeutic stimulation parameters required to produce the preferred therapeutic state may be identified. In some embodiments, these stimulation parameters may be used to apply continuous therapeutic DBS to the target neural structure.
  • the therapeutic stimulation may be adjusted based on measured HFOs.
  • the measured HFO activity is in a preferred state, e.g. if the measured HFOs substantially match a template or if an HFO characteristic frequency is within a desired range, the amplitude of the therapeutic stimulation may be reduced by the signal generator 94 in response to an instruction from the processing unit 92.
  • the amplitude of therapeutic stimulation may be increased or decreased by the signal generator 94 to reposition the HFO activity within the preferred window.
  • non-therapeutic patterned stimulation also enhances HFO activity
  • such activity can be used to track the effects of medication, a disease state or to assist in the placement of electrodes or to decide which electrode of a plurality of electrodes positioned within the brain is the optimal electrode to use for stimulation.
  • equivalent methods to those described herein both for electrode placement and choosing which electrode to use for DBS based on ERNA can also be used to aid in the placement of electrodes and choose an optimal electrode for stimulation.
  • a method for operating the system 90 using closed-loop feedback is provided in which the duty cycle of stimulation is modulated with an aim to minimise stimulation on-time.
  • Figure 22 illustrates a process which may be performed by the system 90.
  • a stimulation signal is generated. Parameters of the stimulation signal are chosen so as to optimise the ERNA and/or HFO activity to preferred states.
  • the stimulus is then applied to an electrode of the lead tip 70 for a period T at step 172.
  • the period T may be a fixed period.
  • the stimulus is applied continuously or periodically until a preferred state of ERNA is reached.
  • the therapeutic stimulation is then stopped and the evoked response are measured at one or more electrodes, the evoked response being to a probe stimulus comprising one or more bursts of pulses applied to the stimulation electrode (at step 174).
  • the probe stimulus may be applied to more than one electrode.
  • the stimulation electrode can be used to measure ERNA instead of or in addition to the one or more other electrodes.
  • the system is then maintained in this state of monitoring until the ERNA becomes undesirable.
  • the determination of whether or not the ERNA is in a preferred or therapeutic state may be performed by comparing the measured response with a template ERNA response, or by comparing a measured ERNA characteristic with a desired range. As soon as it is considered that the state is undesirable at step 176, a stimulation signal is again generated and applied at steps 170 and 172.
  • Figure 23 graphically compares a stimulation regime 178 comprising a patterned therapeutic stimulation signal 182 followed by a non-therapeutic patterned stimulation signal (comprising one or more bursts of pulses) 184 and a corresponding characteristic (e.g. resonant frequency) 180 of the ERNA varying between a preferred state 186 and a less than preferable state 188.
  • a stimulation regime 178 comprising a patterned therapeutic stimulation signal 182 followed by a non-therapeutic patterned stimulation signal (comprising one or more bursts of pulses) 184 and a corresponding characteristic (e.g. resonant frequency) 180 of the ERNA varying between a preferred state 186 and a less than preferable state 188.
  • FIG. 24 illustrates a process which may be performed by the system 90.
  • a stimulation signal is generated. Parameters of the stimulation signal are chosen so as to optimise the HFO activity to a preferred state.
  • the stimulus is then applied to an electrode of the lead tip 70 at step 206. Preferably the stimulus is applied continuously or periodically until a preferred state of HFO is reached. Whilst the stimulation signal is begin applied to the lead tip 70, HFO activity is measured at one or more electrodes (at step 174).
  • the stimulation signal may be applied to more than one electrode.
  • the stimulation electrode can be used to measure HFO activity instead of or in addition to the one or more other electrodes.
  • the system 90 continues to monitor HFO activity until the HFO activity becomes undesirable.
  • the determination of whether or not the HFO activity is in a preferred or therapeutic state may be performed by comparing the measured activity with a template HFO activity or by comparing a measured HFO characteristic with a desired range. As soon as it is considered that the state is undesirable at step 210, the stimulation signal is adjusted and applied at step 206 to the lead tip 70.
  • FIG. 25 illustrates another process which may be performed by the system 90 for controlling DBS stimulation.
  • a stimulation signal is generated. Parameters of the stimulation signal are chosen so as to optimise the HFO activity to a preferred state.
  • the stimulus is then applied to an electrode of the lead tip 70 at step 206. Preferably the stimulus is applied continuously or periodically until a preferred state of HFO is reached. Whilst the stimulation signal is begin applied to the lead tip 70, HFO activity is measured at one or more electrodes (at step 206). In some embodiments the stimulation signal may be applied to more than one electrode. In some embodiments, the stimulation electrode can be used to measure HFO activity instead of or in addition to the one or more other electrodes. Stimulation is applied until HFO activity reaches an optimum state.
  • the determination of whether or not the HFO activity is in an optimum state may be performed by comparing the measured activity with a template HFO activity or by comparing a measured HFO characteristic with a desired range.
  • the applied DBS stimulation amplitude or frequency may be adjusted, for example, by reducing its amplitude of frequency or by ceasing stimulation altogether. This in turn will cause the HFO activity to drift outside of the preferred state.
  • the HFO activity may then be adjusted again at step 214 to bring the HFO activity back to the preferred state, for example, by increasing the amplitude of DBS stimulation or by adjusting the frequency of stimulation.
  • Figures 26a and 26b illustrate two exemplary patterning profiles.
  • the patterned profile includes a period of no stimulation 192 after a continuous stimulation block 190, followed by a burst of pulses 194 and another period of no stimulation 196.
  • the ERNA may be measured and therapeutic stimulation signal adjusted (if required).
  • HFO activity may be measured either during the period of no stimulation, or during stimulation, or both, and therapeutic stimulation may be adjusted accordingly, if required.
  • the system may monitor the ERNA and/or HFO activity after a final pulse of continuous stimulation 198 as shown in Figure 26b. After a period of monitoring 200, the therapeutic stimulation may then be adjusted for a period 202 after which the therapeutic stimulation 198 may be applied with the adjusted parameters. This regime may also be considered as continuous stimulation with periodic missing pulses. To this end, the continuous stimulation may be considered as a burst of pulses, and the period of no stimulation may be considered as the first time period tj as described with reference to Figure 2 above. [0233] The presence and amplitude of ERNA and HFO activity can be dependent on stimulation amplitude.
  • the last pulse before the period of no stimulation may therefore be at a fixed amplitude which is independent of the amplitude of stimulation being applied by other pulses (e.g. therapeutic stimulation), so as to minimise any effect due to resonance dependence on stimulation amplitude or other pulse parameters.
  • Electrodes Whilst in embodiments described above, a single electrode array is used both to stimulate and record an evoked neural response, in other embodiments, electrodes may be distributed on multiple probes or leads in one or more target structures in either or both brain hemispheres. Equally, electrodes either implanted or positioned external to the brain may be used to stimulate or record or both stimulate and record an evoked neural response. In some embodiments, a combination of both microelectrode and macroelectrodes may be used in any foreseeable manner.
  • ERNA and/or HFO measurements may be recorded and tracked over time to monitor the progression or remission of a disease or syndrome, or used as a diagnostic tool (e.g. to classify the patient's neurological condition). Such embodiments may also be used to provide medical alerts to the patient, a caregiver or a clinician in the event that the patient's state (as determined by ERNA/HFO activity) deteriorates towards an undesirable or critical state (e.g. a Parkinsonian crisis).
  • an undesirable or critical state e.g. a Parkinsonian crisis
  • ERNA and/or HFO activity may be used to monitor the effects of medication over time, including the effects of adjusting medication doses, etc. Such an embodiment may also be used to provide medication alerts to the patient to remind them when a dose is required or when a dose has been skipped. Tracking medication effects with ERNA/HFO activity may also provide clinicians with information regarding whether medication is being taken as prescribed or whether medication is becoming less effective and requires dosing adjustment.
  • the 'skipped-pulse' pattern was anticipated to have comparable therapeutic effects to standard 130 Hz DBS, as it causes only a 0.77% reduction in the total number of pulses delivered over time.
  • the 'burst' pattern was anticipated to have minimal therapeutic effects relative to continuous DBS, as only 7.7% of the pulses are delivered, making it a useful probe for investigating activity in the absence of therapy.
  • the median HFO peak frequency immediately post-DBS was 253 Hz, comparable to the median ERNA frequency of the therapeutic 3.38 niA condition (256 Hz), suggesting HFO activity occurs at the same frequency as ERNA during the more continuous skipped- pulse stimulation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Psychology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Developmental Disabilities (AREA)
  • Physiology (AREA)
  • Cardiology (AREA)
  • Electrotherapy Devices (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
PCT/AU2018/050486 2016-08-08 2018-05-21 "systems and methods for monitoring neural activity" Ceased WO2018213872A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US16/616,017 US11298070B2 (en) 2017-05-22 2018-05-21 Systems and methods for monitoring neural activity
CN201880047032.3A CN111200967B (zh) 2017-05-22 2018-05-21 用于监测神经活动的系统和方法
JP2019564887A JP7144450B2 (ja) 2017-05-22 2018-05-21 神経活動をモニタするためのシステム及び方法
EP18804979.5A EP3629913B1 (en) 2017-05-22 2018-05-21 System for monitoring neural activity
US17/691,491 US20220192579A1 (en) 2016-08-08 2022-03-10 Systems and methods for monitoring neural activity

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2017901934A AU2017901934A0 (en) 2017-05-22 Systems and Methods for Monitoring Neural Activity
AU2017901934 2017-05-22
PCT/AU2017/050809 WO2018027259A1 (en) 2016-08-08 2017-08-02 Systems and methods for monitoring neural activity
AUPCT/AU2017/050809 2017-08-02

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/616,017 A-371-Of-International US11298070B2 (en) 2017-05-22 2018-05-21 Systems and methods for monitoring neural activity
US17/691,491 Continuation US20220192579A1 (en) 2016-08-08 2022-03-10 Systems and methods for monitoring neural activity

Publications (1)

Publication Number Publication Date
WO2018213872A1 true WO2018213872A1 (en) 2018-11-29

Family

ID=64395063

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2018/050486 Ceased WO2018213872A1 (en) 2016-08-08 2018-05-21 "systems and methods for monitoring neural activity"

Country Status (5)

Country Link
US (1) US11298070B2 (enExample)
EP (1) EP3629913B1 (enExample)
JP (1) JP7144450B2 (enExample)
CN (1) CN111200967B (enExample)
WO (1) WO2018213872A1 (enExample)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019210371A1 (en) * 2018-05-03 2019-11-07 The Bionics Institute Of Australia Systems and methods for monitoring neural activity
WO2021022332A1 (en) 2019-08-06 2021-02-11 Deep Brain Stimulation Technologies Pty Ltd Systems and methods for monitoring neural activity
WO2021150660A1 (en) * 2020-01-23 2021-07-29 The Cleveland Clinic Foundation Configuring a deep brain stimulation (dbs) system to treat a neurological disorder
WO2023004256A1 (en) * 2021-07-22 2023-01-26 Boston Scientific Neuromodulationcorporation Interpolation methods for neural responses
EP4093499A4 (en) * 2020-01-24 2023-06-28 Deep Brain Stimulation Technologies Pty. Ltd. Systems and methods for monitoring neural activity
US12070603B2 (en) 2021-02-12 2024-08-27 Boston Scientific Neuromodulation Corporation Neural feedback assisted DBS
US12179024B2 (en) 2021-03-18 2024-12-31 Boston Scientific Neuromodulation Corporation Methods and systems for target localization and DBS therapy
US12370367B2 (en) 2020-08-14 2025-07-29 University Of Houston System System and method for determining deep brain stimulation parameters

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220192579A1 (en) * 2016-08-08 2022-06-23 Deep Brain Stimulation Technologies Pty. Ltd. Systems and methods for monitoring neural activity
AU2021324583B2 (en) * 2020-08-10 2024-08-08 Boston Scientific Neuromodulation Corporation Electrical stimulation systems based on stimulation-evoked responses
US12168134B2 (en) * 2020-08-14 2024-12-17 University Of Houston System System and method for locating an implantation site in the brain
EP3961479B1 (de) 2020-08-28 2025-03-12 MicroVision, Inc. Verfahren und vorrichtung zur klassifizierung von targets
US20230092658A1 (en) * 2021-08-24 2023-03-23 Medtronic, Inc. Template-based determination of electrophysiological signal sources
WO2023215176A1 (en) * 2022-05-02 2023-11-09 Medtronic, Inc. Closed-loop deep brain stimulation (dbs) programming based on evoked signals and local field potential (lfp) signals
CN120550331B (zh) * 2025-07-28 2025-10-21 杭州神络医疗科技有限公司 一种神经刺激器的无线供能设备与无线供能方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009009724A1 (en) * 2007-07-11 2009-01-15 Mayo Foundation For Medical Education And Research Seizure forecasting, microseizure precursor events, and related therapeutic methods and devices
US20120150257A1 (en) 2010-12-09 2012-06-14 Dorian Aur Seizure prediction and neurological disorder treatment
US20160074663A1 (en) * 2014-09-11 2016-03-17 Dirk De Ridder System and method for nested neurostimulation
WO2016205231A1 (en) * 2015-06-19 2016-12-22 Duke University Systems and methods for utilizing deep brain stimulation local evoked potentials for the treatment of neurological disorders
WO2018005981A1 (en) * 2016-07-01 2018-01-04 Seton Healthcare Family Prediction of preictal state and seizure onset zones based on high frequency oscillations
WO2018027259A1 (en) * 2016-08-08 2018-02-15 Bionics Institute Systems and methods for monitoring neural activity

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5561526A (en) 1994-05-26 1996-10-01 Lockheed Missiles & Space Company, Inc. Three-dimensional measurement device and system
JP3738456B2 (ja) 1994-11-14 2006-01-25 マツダ株式会社 物品の位置検出方法およびその装置
US6480743B1 (en) 2000-04-05 2002-11-12 Neuropace, Inc. System and method for adaptive brain stimulation
US6066163A (en) 1996-02-02 2000-05-23 John; Michael Sasha Adaptive brain stimulation method and system
US6463328B1 (en) 1996-02-02 2002-10-08 Michael Sasha John Adaptive brain stimulation method and system
JPH1021401A (ja) 1996-07-04 1998-01-23 Canon Inc 三次元情報処理装置
JP3113827B2 (ja) 1996-11-28 2000-12-04 インターナショナル・ビジネス・マシーンズ・コーポレ−ション 矩形オブジェクトの認識方法及び認識装置
US6597954B1 (en) 1997-10-27 2003-07-22 Neuropace, Inc. System and method for controlling epileptic seizures with spatially separated detection and stimulation electrodes
JP2002516443A (ja) 1998-05-15 2002-06-04 トリコーダー テクノロジー ピーエルシー ３次元表示のための方法および装置
US6137491A (en) 1998-06-05 2000-10-24 Microsoft Corporation Method and apparatus for reconstructing geometry using geometrically constrained structure from motion with points on planes
US6748112B1 (en) 1998-07-28 2004-06-08 General Electric Company Method and apparatus for finding shape deformations in objects having smooth surfaces
US7277758B2 (en) 1998-08-05 2007-10-02 Neurovista Corporation Methods and systems for predicting future symptomatology in a patient suffering from a neurological or psychiatric disorder
JP2000175176A (ja) 1998-12-04 2000-06-23 Hitachi Ltd 移動物体の監視方法および画像監視装置
US6539263B1 (en) 1999-06-11 2003-03-25 Cornell Research Foundation, Inc. Feedback mechanism for deep brain stimulation
US7305268B2 (en) 2000-07-13 2007-12-04 Northstar Neurscience, Inc. Systems and methods for automatically optimizing stimulus parameters and electrode configurations for neuro-stimulators
AUPR061600A0 (en) 2000-10-10 2000-11-02 D & E Consulting Pty Ltd Method and apparatus for controlling repetitive nervous system malfunction
US7089059B1 (en) 2000-11-03 2006-08-08 Pless Benjamin D Predicting susceptibility to neurological dysfunction based on measured neural electrophysiology
JP4167390B2 (ja) 2000-11-20 2008-10-15 日本電気株式会社 物体照合方法，物体照合装置，およびそのプログラムを記録した記録媒体
US6578869B2 (en) 2001-03-26 2003-06-17 Trw Inc. Vehicle occupant position sensor utilizing image focus attributes
US6671555B2 (en) 2001-04-27 2003-12-30 Medtronic, Inc. Closed loop neuromodulation for suppression of epileptic activity
US6700668B2 (en) 2002-06-25 2004-03-02 General Electric Company Method of measuring a part with a wide range of surface reflectivities
US6922632B2 (en) 2002-08-09 2005-07-26 Intersense, Inc. Tracking, auto-calibration, and map-building system
US6985238B2 (en) 2002-09-25 2006-01-10 General Electric Company Non-contact measurement system for large airfoils
WO2004043536A1 (en) 2002-11-12 2004-05-27 Neuropace, Inc. System for adaptive brain stimulation
DE60331351D1 (de) 2002-12-06 2010-04-01 Boston Scient Neuromodulation Verfahren zur feststellung von stimulationsparametern
US7639741B1 (en) 2002-12-06 2009-12-29 Altera Corporation Temporal filtering using object motion estimation
US7408986B2 (en) 2003-06-13 2008-08-05 Microsoft Corporation Increasing motion smoothness using frame interpolation with motion analysis
DE10355652A1 (de) 2003-11-28 2005-06-30 Forschungszentrum Jülich GmbH Verfahren und Vorrichtung zur Desynchronisation neuronaler Hirnaktivität
WO2006019764A2 (en) 2004-07-15 2006-02-23 Northstar Neuroscience, Inc. Systems and methods for enhancing or affecting neural stimulation efficiency and/or efficacy
JP3779308B2 (ja) 2004-07-21 2006-05-24 独立行政法人科学技術振興機構 カメラ校正システム及び三次元計測システム
US7447558B2 (en) 2004-09-18 2008-11-04 The Ohio Willow Wood Company Apparatus for determining a three dimensional shape of an object
WO2007018572A2 (en) 2004-11-08 2007-02-15 Bell Helicopter Textron Inc. Flight system with three feedback control loops
US7684602B2 (en) 2004-11-18 2010-03-23 Siemens Medical Solutions Usa, Inc. Method and system for local visualization for tubular structures
US8825166B2 (en) 2005-01-21 2014-09-02 John Sasha John Multiple-symptom medical treatment with roving-based neurostimulation
US8082120B2 (en) 2005-03-11 2011-12-20 Creaform Inc. Hand-held self-referenced apparatus for three-dimensional scanning
ATE518113T1 (de) 2005-03-11 2011-08-15 Creaform Inc Selbstreferenziertes system und vorrichtung zum dreidimensionalen scannen
US7724379B2 (en) 2005-05-12 2010-05-25 Technodream21, Inc. 3-Dimensional shape measuring method and device thereof
US7343200B2 (en) 2005-06-01 2008-03-11 Advanced Bionics, Llc Methods and systems for automatically determining a neural response threshold current level
US7275008B2 (en) 2005-09-02 2007-09-25 Nokia Corporation Calibration of 3D field sensors
WO2007056541A2 (en) 2005-11-08 2007-05-18 Young Garrett J Apparatus and method for generating light from multi - primary colors
US7929751B2 (en) 2005-11-09 2011-04-19 Gi, Llc Method and apparatus for absolute-coordinate three-dimensional surface imaging
JP4650752B2 (ja) 2005-12-16 2011-03-16 株式会社Ihi 自己位置同定方法と装置および三次元形状の計測方法と装置
US7567713B2 (en) 2006-02-08 2009-07-28 Mitutoyo Corporation Method utilizing intensity interpolation for measuring edge locations in a high precision machine vision inspection system
US20070201859A1 (en) 2006-02-24 2007-08-30 Logitech Europe S.A. Method and system for use of 3D sensors in an image capture device
US8190251B2 (en) 2006-03-24 2012-05-29 Medtronic, Inc. Method and apparatus for the treatment of movement disorders
ATE441087T1 (de) 2006-04-27 2009-09-15 3D Scanners Ltd Optische rastersonde
DE602006006818D1 (de) 2006-06-30 2009-06-25 Gen Electric Verfahren und System für Mehrkanalbiosignal-Verarbeitung
US8321025B2 (en) 2006-07-31 2012-11-27 Cranial Medical Systems, Inc. Lead and methods for brain monitoring and modulation
US8280514B2 (en) 2006-10-31 2012-10-02 Advanced Neuromodulation Systems, Inc. Identifying areas of the brain by examining the neuronal signals
US7768655B2 (en) 2006-12-20 2010-08-03 General Electric Company Methods and system for measuring an object
DE102007022361A1 (de) 2007-05-04 2008-11-06 Friedrich-Schiller-Universität Jena Vorrichtung und Verfahren zum berührungslosen Erfassen räumlicher Koordinaten einer Oberfläche
WO2008144370A1 (en) 2007-05-16 2008-11-27 Honda Motor Co., Ltd. Camera-projector duality: multi-projector 3d reconstruction
US7768656B2 (en) 2007-08-28 2010-08-03 Artec Group, Inc. System and method for three-dimensional measurement of the shape of material objects
US7983757B2 (en) 2007-10-26 2011-07-19 Medtronic, Inc. Medical device configuration based on sensed brain signals
JP5412169B2 (ja) 2008-04-23 2014-02-12 株式会社日立ハイテクノロジーズ 欠陥観察方法及び欠陥観察装置
EP2313737B1 (en) 2008-08-06 2018-11-14 Creaform Inc. System for adaptive three-dimensional scanning of surface characteristics
WO2010025226A1 (en) * 2008-08-29 2010-03-04 Emory University Microelectrode stimulation for treatment of epilepsy or other neurologic disorder
WO2010056501A1 (en) 2008-11-14 2010-05-20 Boston Scientific Neuromodulation Corporation Implantable medical device that uses electrical current steering by means of output impedance modulation
US20100142846A1 (en) 2008-12-05 2010-06-10 Tandent Vision Science, Inc. Solver for image segregation
US8260050B2 (en) 2008-12-05 2012-09-04 Tandent Vision Science, Inc. Test bed for optimizing an image segregation
US8139867B2 (en) 2008-12-05 2012-03-20 Tandent Vision Science, Inc. Image segregation system architecture
US8139850B2 (en) 2008-12-05 2012-03-20 Tandent Vision Science, Inc. Constraint generation for use in image segregation
US8774923B2 (en) 2009-03-22 2014-07-08 Sorin Crm Sas Optimal deep brain stimulation therapy with Q learning
JP5602392B2 (ja) 2009-06-25 2014-10-08 キヤノン株式会社 情報処理装置、情報処理方法およびプログラム
CN101620676B (zh) 2009-07-02 2012-05-23 浙江省电力公司 绝缘子轮廓的快速图像识别方法
US20110028859A1 (en) 2009-07-31 2011-02-03 Neuropace, Inc. Methods, Systems and Devices for Monitoring a Target in a Neural System and Facilitating or Controlling a Cell Therapy
US8914115B2 (en) 2009-12-03 2014-12-16 Medtronic, Inc. Selecting therapy cycle parameters based on monitored brain signal
CN102905757B (zh) 2010-03-22 2016-02-17 纽约城市大学研究基金会 电荷增强神经电刺激系统
WO2011130488A2 (en) * 2010-04-15 2011-10-20 Cardiac Pacemakers, Inc. Autonomic modulation using transient response with intermittent neural stimulation
JP5625490B2 (ja) 2010-05-25 2014-11-19 セイコーエプソン株式会社 プロジェクター、投射状態調整方法及び投射状態調整プログラム
CN102338616B (zh) 2010-07-22 2016-08-17 首都师范大学 结合定位定姿系统的三维旋转扫描测量系统及方法
JP4940461B2 (ja) 2010-07-27 2012-05-30 株式会社三次元メディア ３次元物体認識装置及び３次元物体認識方法
US8798764B2 (en) 2010-09-01 2014-08-05 Medtronic, Inc. Symmetrical physiological signal sensing with a medical device
US8583237B2 (en) 2010-09-13 2013-11-12 Cranial Medical Systems, Inc. Devices and methods for tissue modulation and monitoring
EP2699309B1 (en) 2011-04-20 2017-08-09 Medtronic, Inc. Electrical therapy parameter determination based on a bioelectrical resonance response
CN103649680B (zh) 2011-06-07 2016-11-09 形创有限公司 用于3d扫描的传感器定位
US9888861B2 (en) 2011-08-25 2018-02-13 Medtronic, Inc. Method and apparatus for detecting a biomarker in the presence of electrical stimulation
US20130150918A1 (en) 2011-12-08 2013-06-13 Boston Scientific Neuromodulation Corporation System and method for automatically training a neurostimulation system
EP2814565B1 (en) 2012-02-19 2019-04-03 Medtronic Inc. Brain stimulation response profiling
US9338447B1 (en) 2012-03-14 2016-05-10 Amazon Technologies, Inc. Calibrating devices by selecting images having a target having fiducial features
US8662676B1 (en) 2012-03-14 2014-03-04 Rawles Llc Automatic projector calibration
US8892208B2 (en) 2012-06-13 2014-11-18 The Regents Of The University Of Michigan Closed-loop neural stimulation
US9295838B2 (en) 2012-10-31 2016-03-29 The Regents Of The University Of California Methods and systems for treating neurological movement disorders
US10105091B2 (en) 2013-03-12 2018-10-23 The Cleveland Clinic Foundation Methods of using nerve evoked potentials to monitor a surgical procedure
US9782590B2 (en) 2013-10-18 2017-10-10 Functional Neuromodulation, Inc. Brain stimulation system including diagnostic tool
WO2015069632A1 (en) 2013-11-05 2015-05-14 The University Of North Carolina At Chapel Hill Methods, apparatuses and systems for transcranial stimulation
JP6730185B2 (ja) 2013-11-15 2020-07-29 サルーダ・メディカル・ピーティーワイ・リミテッド 脳神経電位のモニタリング
US9421379B2 (en) 2014-02-25 2016-08-23 Boston Scientific Neuromodulation Corporation Neuromodulation system incorporating multivariate sensing, multivariable pattern recognition, and patient specific adaptation
US9325973B1 (en) 2014-07-08 2016-04-26 Aquifi, Inc. Dynamically reconfigurable optical pattern generator module useable with a system to rapidly reconstruct three-dimensional data
US20160045127A1 (en) * 2014-08-15 2016-02-18 The Regents Of The University Of Michigan Automated detector and classifier of high frequency oscillations and indicator seizure onset
EP3402567B1 (en) 2016-01-15 2022-03-09 Stimwave Technologies Incorporated An implantable relay module

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009009724A1 (en) * 2007-07-11 2009-01-15 Mayo Foundation For Medical Education And Research Seizure forecasting, microseizure precursor events, and related therapeutic methods and devices
US20120150257A1 (en) 2010-12-09 2012-06-14 Dorian Aur Seizure prediction and neurological disorder treatment
US20160074663A1 (en) * 2014-09-11 2016-03-17 Dirk De Ridder System and method for nested neurostimulation
WO2016205231A1 (en) * 2015-06-19 2016-12-22 Duke University Systems and methods for utilizing deep brain stimulation local evoked potentials for the treatment of neurological disorders
WO2018005981A1 (en) * 2016-07-01 2018-01-04 Seton Healthcare Family Prediction of preictal state and seizure onset zones based on high frequency oscillations
WO2018027259A1 (en) * 2016-08-08 2018-02-15 Bionics Institute Systems and methods for monitoring neural activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3629913A4

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019210371A1 (en) * 2018-05-03 2019-11-07 The Bionics Institute Of Australia Systems and methods for monitoring neural activity
US12064630B2 (en) 2018-05-03 2024-08-20 Deep Brain Stimulation Technologies Pty. Ltd. Systems and methods for monitoring neural activity
EP4010066A4 (en) * 2019-08-06 2022-09-07 Deep Brain Stimulation Technologies Pty Ltd SYSTEMS AND METHODS FOR MONITORING NERVE ACTIVITY
JP2022543160A (ja) * 2019-08-06 2022-10-07 ディープ・ブレイン・スティムレーション・テクノロジーズ・ピーティーワイ・リミテッド 神経活動をモニタするためのシステム及び方法
WO2021022332A1 (en) 2019-08-06 2021-02-11 Deep Brain Stimulation Technologies Pty Ltd Systems and methods for monitoring neural activity
CN114513986A (zh) * 2019-08-06 2022-05-17 深部脑刺激技术有限公司 用于监测神经活动的系统和方法
US12194297B2 (en) 2020-01-23 2025-01-14 The Cleveland Clinic Foundation Configuring a deep brain stimulation (DBS) system to treat a neurological disorder
WO2021150660A1 (en) * 2020-01-23 2021-07-29 The Cleveland Clinic Foundation Configuring a deep brain stimulation (dbs) system to treat a neurological disorder
EP4467185A3 (en) * 2020-01-23 2024-12-04 The Cleveland Clinic Foundation Configuring a deep brain stimulation (dbs) system to treat a neurological disorder
EP4093499A4 (en) * 2020-01-24 2023-06-28 Deep Brain Stimulation Technologies Pty. Ltd. Systems and methods for monitoring neural activity
US12370367B2 (en) 2020-08-14 2025-07-29 University Of Houston System System and method for determining deep brain stimulation parameters
US12070603B2 (en) 2021-02-12 2024-08-27 Boston Scientific Neuromodulation Corporation Neural feedback assisted DBS
US12179024B2 (en) 2021-03-18 2024-12-31 Boston Scientific Neuromodulation Corporation Methods and systems for target localization and DBS therapy
US12324918B2 (en) 2021-03-18 2025-06-10 Boston Scientific Neuromodulation Corporation Methods and systems for lead movement detection and response in DBS therapy
WO2023004256A1 (en) * 2021-07-22 2023-01-26 Boston Scientific Neuromodulationcorporation Interpolation methods for neural responses
US12377274B2 (en) 2021-07-22 2025-08-05 Boston Scientific Neuromodulation Corporation Interpolation methods for neural responses

Also Published As

Publication number Publication date
EP3629913A4 (en) 2020-12-30
CN111200967A (zh) 2020-05-26
CN111200967B (zh) 2023-06-06
JP2020521544A (ja) 2020-07-27
JP7144450B2 (ja) 2022-09-29
US11298070B2 (en) 2022-04-12
US20200138324A1 (en) 2020-05-07
EP3629913C0 (en) 2024-05-15
EP3629913B1 (en) 2024-05-15
EP3629913A1 (en) 2020-04-08

Similar Documents

Publication Publication Date Title
US11890478B2 (en) Systems and methods for monitoring neural activity
EP3629913B1 (en) System for monitoring neural activity
US12064630B2 (en) Systems and methods for monitoring neural activity
AU2013306411B2 (en) Ultrasound diagnostic and therapy management system and associated method
EP4010066B1 (en) Systems and methods for monitoring neural activity
US20220192579A1 (en) Systems and methods for monitoring neural activity
EP4093499B1 (en) Systems for monitoring neural activity

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18804979

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019564887

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2018804979

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2018804979

Country of ref document: EP

Effective date: 20200102